2025-2026 Regular Session • US Congress Legislature
SB1040: Drug Competition Enhancement Act
Legislative Summary
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Demographic Impact
Overall analysis of equity impact
70% Positive
Medium ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
3/13/2025
Read twice and referred to the Committee on the Judiciary.
Senate
4/3/2025
Committee on the Judiciary. Ordered to be reported with an amendment favorably.
Senate
4/10/2025
Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
Senate
4/10/2025
Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
Senate
Status Information
Current Status
Introduced(3/13/2025)
Chamber
Senate
Sponsors
Republican: 2
Democrat: 2
Primary Sponsor
John Cornyn
Republican